• Home
  • Media Events
  • Biotech Consortium India Ltd. (BCIL) and SRHU (SRHU) Forge Partnership for Technology Transfer and Commercialization

Biotech Consortium India Ltd. (BCIL) and SRHU (SRHU) Forge Partnership for Technology Transfer and Commercialization

Published on: May 10, 2024

Biotech Consortium India Ltd. (BCIL) and Swami Rama Himalayan University (SRHU) Forge Partnership for Technology Transfer and Commercialization

In a significant development aimed at fostering innovation and technology transfer, Biotech Consortium India Ltd. (BCIL) and Swami Rama Himalayan University (SRHU) have entered into a Memorandum of Agreement (MoA) to collaborate on the transfer and commercialization of intellectual properties (IPs) and technologies developed at SRHU. The MoU was signed on 29 March 2024

Under the agreement, BCIL, a company promoted by the Department of Biotechnology (DBT), Ministry of Science and Technology, Government of India, will work closely with SRHU to identify promising technologies and facilitate their transfer to suitable companies in India and abroad for translation and commercialization.

Dr. Purnima Sharma, Managing Director of BCIL, emphasized the importance of robust IP management and public-private partnerships in driving innovation and economic growth. She expressed confidence in the partnership’s potential to create new opportunities for industry collaboration and technology commercialization.

SRHU, known for its research excellence and commitment to technology development, will play a crucial role in providing the necessary technical expertise and know-how for the successful transfer of technologies. Dr. Rajendra Dobhal, Vice Chancellor of SRHU, highlighted the university’s dedication to fostering a culture of innovation and entrepreneurship among its faculty and students.

Key highlights of the MOU include provisions for technology evaluation, licensing agreements, IP management, and quality assurance measures. Both parties have committed to a ten-year partnership with provisions for extension based on mutual consent

Speaking on behalf of SRHU, Dr. Rajendra Dobhal emphasized the university’s commitment to promoting a conducive environment for technology transfer and commercialization. He expressed optimism about the collaboration’s potential to drive socio-economic development and create new avenues for research and innovation in the region.

The partnership between BCIL and SRHU underscores the importance of collaboration between academia and industry in advancing technology development and fostering innovation-driven growth. It is expected to pave the way for enhanced research collaboration, public-private partnerships, and technology commercialization efforts in the biotechnology sector.

WhatsApp-Image-2024-05-08-at-3.13.09-PM
WhatsApp-Image-2024-05-08-at-3.13.12-PM
   Admissions Form         

Admission Open For 2025

×
International Endowed Chair Professor

Prof Rakesh Kumar

Prof Rakesh Kumar is the Founder and President of the Breast Cancer in Young Women Foundation (USA), dedicated to vaddressing the distinct issues affecting young women with breast cancer. He also serves as the International Endowed Chair Professor at the Cancer Research Institute of the Himalayan Institute of Medical Sciences. Additionally, he holds adjunct professorships at Rutgers New Jersey Medical School and Virginia Commonwealth University.

Dr Kumar earned his Ph.D. from the All India Institute of Medical Sciences in 1984 and began his research career at Memorial Sloan Kettering Cancer Center in January 1986. From 1988 to 2017, he held various academic and leadership positions —including faculty member, tenured professor, distinguished professor, endowed chair, department chair, and research leader—at esteemed institutions such as Memorial Sloan Kettering Cancer Center in New York and the University of Texas MD Anderson Cancer Center in Houston. From 2017 to 2022, he served as the National Chair for Cancer Research for the Government of India and as a distinguished professor, continuing his innovative work in breast cancer research.

With nearly 40 years of research and professional experience, Dr. Kumar has made conceptual contributions to the field of cancer research (h-index 108, citations >50,000). He has authored over 325 peer-reviewed publications, edited or co-edited nine books, and delivered 290 invited lectures worldwide. His work has been featured on the covers of 18 major cancer journals and has been highlighted in institutional research reports of the MD Anderson Cancer Center.

A passionate educator and mentor, Dr. Kumar has guided 67 trainees throughout his career. He serves on the editorial boards of multiple leading cancer journals and has served on the editorial boards of 21 top cancer journals. His global reputation is further demonstrated by his participation in about 100 peer-review panels for cancer research funding in the US and internationally over the past 28 years.

Dr. Kumar's innovative research has earned him numerous prestigious honors, including the Hinkle Society Faculty Award at Penn State University (1994), the Dalla/Fort Worth Living Legend Faculty Achievement Award in Basic Sciences (2004), the Ranbaxy Research Award (2006), and the Lifetime Achievement Award from the American Association of Indian Scientists in Cancer Research (2013), among others. Dr. Kumar's pioneering research continues to have a profound influence on the fields of oncology and breast cancer, opening up new opportunities for biomedical scientists and trainees worldwide.